Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 1/20 | 0.34 |
| ▸ | GIPR | P48546 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.30 |
| ▸ | RHEB | Q15382 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4897265 | 0.91 | MAPK10 (0.37) | ALDH1A1MAPK10MCHR1HDAC1HDAC2 | |
| SCHEMBL4899822 | 0.91 | HRH2 (0.33) | DRD2DRD4DRD3HDAC6HRH2 | |
| SCHEMBL4894087 | 0.87 | PPARA (0.36) | — | |
| SCHEMBL4901698 | 0.86 | ALDH1A1 (0.38) | GCGRGIPRALDH1A1MAPK10MCHR1 | |
| SCHEMBL4895489 | 0.84 | ALDH1A1 (0.39) | ALDH1A1MAPK10MCHR1HDAC1HDAC6 | |
| SCHEMBL4898669 | 0.84 | ALDH1A1 (0.39) | ALDH1A1MAPK10MCHR1HDAC1HDAC6 | |
| SCHEMBL4900432 | 0.84 | NR1H4 (0.31) | HDAC1HDAC2HDAC6 | |
| SCHEMBL4898720 | 0.84 | MAPK8 (0.36) | ALDH1A1MAPK10 | |
| SCHEMBL4898519 | 0.84 | ALDH1A1 (0.34) | GCGRGIPRALDH1A1MAPK10MCHR1 | |
| SCHEMBL4889733 | 0.84 | ALDH1A1 (0.38) | ALDH1A1MAPK10MCHR1HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | METABASIS THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | claimed |
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | METABASIS THERAPEUTICS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070867-A1 | 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases | PPM1B, PPM1D, PTPRS | GCGR 674/4885GIPR 163/4885ALDH1A1 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.